Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase

Systemic mastocytosis (SM) comprises a group of rare disorders resulting from tissue infiltration by pathological mast cells. In a percentage ranging from 5 to 40% in various patient series, SM appears to be associated with an accompanying hematologic neoplasm (SM-AHN). The coexistence of SM with ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Fokoloros, Christos, Foukas, Periklis, Georgakopoulos, Nikolaos, Tsakiraki, Zoi, Bouchla, Anthi, Pappa, Vasilliki, Katoulis, Alexandros, Makris, Michael, Papageorgiou, Sotirios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649302/
https://www.ncbi.nlm.nih.gov/pubmed/36389397
http://dx.doi.org/10.1155/2022/7251658
Descripción
Sumario:Systemic mastocytosis (SM) comprises a group of rare disorders resulting from tissue infiltration by pathological mast cells. In a percentage ranging from 5 to 40% in various patient series, SM appears to be associated with an accompanying hematologic neoplasm (SM-AHN). The coexistence of SM with chronic myelogenous leukemia (CML) is extremely rare with only 3 cases in the literature. The natural course of CML has changed dramatically over the past 2 decades with the use of tyrosine kinase inhibitors (TKIs). We report a case of diagnosing SM in a patient in complete molecular remission of CML after stopping TKI treatment.

Ejemplares similares